Synonyms: UBX-1325 | UBX1325
Compound class:
Synthetic organic
Comment: Foselutoclax (UBX1325) is a small-molecule inhibitor of BCL-xL that has a senolytic action [2]. Pharmacological elimination of senescent cells is a mechanism that is under investigation to treat pathologies that are promoted in the presence of senescent cells. This senolytic strategy is considered to be an alternative to anti-vascular endothelial growth factor therapies such as aflibercept in degenerative edematous retinal conditions (e.g. diabetic retinopathy) [3].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
International Nonproprietary Names ![]() |
|
INN number | INN |
12897 | foselutoclax |
Synonyms ![]() |
UBX-1325 | UBX1325 |
Database Links ![]() |
|
CAS Registry No. | 2271269-01-1 (source: WHO INN record) |
GtoPdb PubChem SID | 496703336 |
PubChem CID | 147562879 |
Search Google for chemical match using the InChIKey | FSZILRQCEAUYPL-VQJSHJPSSA-N |
Search Google for chemicals with the same backbone | FSZILRQCEAUYPL |
Search PubMed clinical trials | foselutoclax |
Search PubMed titles | foselutoclax |
Search PubMed titles/abstracts | foselutoclax |
UniChem Compound Search for chemical match using the InChIKey | FSZILRQCEAUYPL-VQJSHJPSSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | FSZILRQCEAUYPL-VQJSHJPSSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
UBX1325 (links to external site)
Cat. No. HY-150069 |